[go: up one dir, main page]

PE20080183A1 - Terapias de combinacion de tra - Google Patents

Terapias de combinacion de tra

Info

Publication number
PE20080183A1
PE20080183A1 PE2007000416A PE2007000416A PE20080183A1 PE 20080183 A1 PE20080183 A1 PE 20080183A1 PE 2007000416 A PE2007000416 A PE 2007000416A PE 2007000416 A PE2007000416 A PE 2007000416A PE 20080183 A1 PE20080183 A1 PE 20080183A1
Authority
PE
Peru
Prior art keywords
refers
tra
receptor antagonist
combination therapies
receptor
Prior art date
Application number
PE2007000416A
Other languages
English (en)
Inventor
Enrico P Veltri
William J Greenlee
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38458156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080183(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20080183A1 publication Critical patent/PE20080183A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN ANTAGONISTA RECEPTOR DE TROMBINA Y UN AGENTE CARDIOVASCULAR SELECCIONADO DE BLOQUEDORES DE CANALES DE CALCIO TAL COMO AMLODIPINA, DILTIAZEM, VERAPAMIL, ENTRE OTROS, ESTATINAS TALES COMO FLUVASTATINA, LOVASTATINA, PRAVASTATINA, ENTRE OTROS, HEPARINAS DE BAJO PESO MOLECULAR SELECCIONADO DE DALTEPARINA, ARDEPARINA, ENOXAPARINA, ENTRE OTROS, ANTIARRITMICOS SELECCIONADOS DE DOFETILIDA, ATENOLOL, PROPANOLOL, ENTRE OTROS, BLOQUEDORES ADRENERGICOS, IECA, BLOQUEADOR DEL RECEPTOR ANGIOTENSINA II, ANTAGONISTA DE ENDOTELINA, ENTRE OTROS. UN ANTAGONISTA RECEPTOR DE TROMBINA ES A, B, C, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE SINDROMES CORONARIOS Y PREVENCION SECUNDARIA EN PACIENTES SUCEPTIBLES A EVENTOS CARDIOVASCULARES
PE2007000416A 2006-04-06 2007-04-04 Terapias de combinacion de tra PE20080183A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79046906P 2006-04-06 2006-04-06
US80861106P 2006-05-26 2006-05-26
US80978506P 2006-05-31 2006-05-31
US83948406P 2006-08-23 2006-08-23
US83947406P 2006-08-23 2006-08-23

Publications (1)

Publication Number Publication Date
PE20080183A1 true PE20080183A1 (es) 2008-03-10

Family

ID=38458156

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000416A PE20080183A1 (es) 2006-04-06 2007-04-04 Terapias de combinacion de tra

Country Status (11)

Country Link
EP (1) EP2001471A1 (es)
JP (1) JP2009532487A (es)
AR (1) AR060354A1 (es)
AU (1) AU2007235353A1 (es)
BR (1) BRPI0710840A2 (es)
CA (1) CA2648613A1 (es)
MX (1) MX2008012933A (es)
NO (1) NO20084677L (es)
PE (1) PE20080183A1 (es)
TW (1) TW200812619A (es)
WO (1) WO2007117621A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
CA2708418C (en) * 2007-12-11 2013-11-12 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones for the treatment and/or prophylaxis of heart failure
MX2010007527A (es) * 2008-01-11 2010-10-05 Eisai R&D Man Co Ltd Composicion farmaceutica, uso del derivado 2-iminopirrolidina para la produccion de la composicion farmaceutica y kit para el tratamiento o mejora de enfermedaes cardiacas.
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
WO2010144339A2 (en) * 2009-06-08 2010-12-16 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
US20130183392A1 (en) * 2011-07-15 2013-07-18 Steven Moore Insect repellant and system
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
CN105125504A (zh) * 2015-09-17 2015-12-09 青岛华之草医药科技有限公司 一种降血脂药物匹伐他汀钙组合物颗粒剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
ATE455774T1 (de) * 2002-04-16 2010-02-15 Schering Corp Trizyklische thrombinrezeptorantagonisten
CA2567981C (en) * 2004-05-28 2010-08-31 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
RU2408594C2 (ru) * 2004-10-08 2011-01-10 Шеринг Корпорейшн Антагонисты рецептора тромбина
US7776889B2 (en) * 2005-03-31 2010-08-17 Schering Corporation Spirocyclic thrombin receptor antagonists
JP2009521472A (ja) * 2005-12-22 2009-06-04 シェーリング コーポレイション 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト
AR058400A1 (es) * 2005-12-22 2008-01-30 Schering Corp Derivados de oxazoloisoquinolina como antagonistas del receptor de trombina

Also Published As

Publication number Publication date
BRPI0710840A2 (pt) 2011-08-23
EP2001471A1 (en) 2008-12-17
MX2008012933A (es) 2008-10-15
WO2007117621A1 (en) 2007-10-18
TW200812619A (en) 2008-03-16
CA2648613A1 (en) 2007-10-18
NO20084677L (no) 2008-11-05
AR060354A1 (es) 2008-06-11
JP2009532487A (ja) 2009-09-10
AU2007235353A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
PE20080183A1 (es) Terapias de combinacion de tra
GT201400102A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
CL2013000713A1 (es) Compuestos pirazin-2-cabonil-imino-1,3,8-triaza-espiro-[4.5]-decan-sustituidos, bloqueadores del canal de sodio epitelial (enac); composicion farmaceutica que los incluye; metodo de prevencion o tratamiento; y su uso para tratar una enfermedad o condicion mediada por el bloqueo del canal de sodio epitelial.
HN2011002022A (es) Composicion farmaceutica solida que comprende amlodipina y losartan
MX2012003207A (es) Metodo y composicion para tratar la demencia de tipo alzheimer.
GT201300122A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
DOP2011000120A (es) Antagonistas del receptor de orexina de isonicotinamida
UY32819A (es) Composiciones farmaceuticas de uso oftalmico de antagonistas del receptor dp2
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
ZA201007170B (en) Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
CL2013003527A1 (es) Compuestos heterociclicos antagonistas de los receptores muscarinicos y agonistas del receptor beta2 adrenergico; su composicion farmaceutica; su combinacion; un dispositivo y su uso en la prevencion y/o el tratamiento de enfermedades bronco-obstructivas o inflamatorias como asma y epoc.
PH12012500754A1 (en) Pharmaceutical composition comprising oligopeptides
UY37981A (es) Novedosos antagonistas del receptor b2 de bradiquinina
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
AR080295A1 (es) Composiciones para el cuidado bucal y metodos de tratamiento
CL2008000430A1 (es) Compuestos derivados de heterociclos condensados sustituidos; composicion farmaceutica que comprende a dichos compuestos, utiles para el tratamiento de una o mas condiciones asociadas con receptores adrenergicos a2c, tales como congestion asociada a
ECSP15007358A (es) Pirrol carboxamidas fluorometilo sustituidas
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
MX2014007042A (es) Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu.
PE20141049A1 (es) Composicion farmaceutica antihipertensiva
CR20110302A (es) ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3
UY33509A (es) Metodos y composiciones para el tratamiento de la alergia
UY38707A (es) Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
CL2009000660A1 (es) Uso de un antagonista del receptor 2 activado con proteasa (par2) para tratar, inhibir o aliviar el dolor.
HN2012001262A (es) Nuevos derivados de 8heterociclo-piperidina condensada)-( piperazinil)-1-alcanona o de (heterociclo-pirrolidina condensada)-(piperazinil)-1-alcanona y su utilizacion como inhibidores de p75

Legal Events

Date Code Title Description
FC Refusal